Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up

Pituitary apoplexy is a clinical syndrome caused by hemorrhage or infarction of a pituitary adenoma. There have been a few reports in the literature of rapid onset of pituitary apoplexy after goserelin injection. To the best of our knowledge, there is no publication in the literature reporting re-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Aljabri, Belal, Lilleby, Wolfgang, Switlyk, Marta D., Tafjord, Gunnar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044649/
https://www.ncbi.nlm.nih.gov/pubmed/33868933
http://dx.doi.org/10.1016/j.eucr.2021.101648
_version_ 1783678533160140800
author Aljabri, Belal
Lilleby, Wolfgang
Switlyk, Marta D.
Tafjord, Gunnar
author_facet Aljabri, Belal
Lilleby, Wolfgang
Switlyk, Marta D.
Tafjord, Gunnar
author_sort Aljabri, Belal
collection PubMed
description Pituitary apoplexy is a clinical syndrome caused by hemorrhage or infarction of a pituitary adenoma. There have been a few reports in the literature of rapid onset of pituitary apoplexy after goserelin injection. To the best of our knowledge, there is no publication in the literature reporting re-introducing goserelin therapy for patients with prostate cancer after the onset of pituitary apoplexy. In this case report, we present the onset and clinico-radiological course of pituitary apoplexy induced by the initiation of goserelin and during continuation of goserelin with up to five-years follow-up.
format Online
Article
Text
id pubmed-8044649
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80446492021-04-16 Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up Aljabri, Belal Lilleby, Wolfgang Switlyk, Marta D. Tafjord, Gunnar Urol Case Rep Oncology Pituitary apoplexy is a clinical syndrome caused by hemorrhage or infarction of a pituitary adenoma. There have been a few reports in the literature of rapid onset of pituitary apoplexy after goserelin injection. To the best of our knowledge, there is no publication in the literature reporting re-introducing goserelin therapy for patients with prostate cancer after the onset of pituitary apoplexy. In this case report, we present the onset and clinico-radiological course of pituitary apoplexy induced by the initiation of goserelin and during continuation of goserelin with up to five-years follow-up. Elsevier 2021-03-23 /pmc/articles/PMC8044649/ /pubmed/33868933 http://dx.doi.org/10.1016/j.eucr.2021.101648 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Oncology
Aljabri, Belal
Lilleby, Wolfgang
Switlyk, Marta D.
Tafjord, Gunnar
Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
title Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
title_full Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
title_fullStr Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
title_full_unstemmed Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
title_short Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
title_sort restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044649/
https://www.ncbi.nlm.nih.gov/pubmed/33868933
http://dx.doi.org/10.1016/j.eucr.2021.101648
work_keys_str_mv AT aljabribelal restartofandrogendeprivationtherapyaftergoserelininducedpituitaryapoplexyinapatientwithdisseminatedprostatecanceracasereportandfiveyearsfollowup
AT lillebywolfgang restartofandrogendeprivationtherapyaftergoserelininducedpituitaryapoplexyinapatientwithdisseminatedprostatecanceracasereportandfiveyearsfollowup
AT switlykmartad restartofandrogendeprivationtherapyaftergoserelininducedpituitaryapoplexyinapatientwithdisseminatedprostatecanceracasereportandfiveyearsfollowup
AT tafjordgunnar restartofandrogendeprivationtherapyaftergoserelininducedpituitaryapoplexyinapatientwithdisseminatedprostatecanceracasereportandfiveyearsfollowup

Ejemplares similares